Glaucoma Global Clinical Trials Review, H2, 2016

 

Rating

4.8 Star Rating for report Glaucoma Global Clinical Trials Review, H2, 2016
4.8 / 5 stars rating
Pages: 563
Price: $2500.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
GlobalData's clinical trial report, "Glaucoma Global Clinical Trials Review, H2, 2016" provides an overview of Glaucoma clinical trials scenario. This report provides top line data relating to the clinical trials on Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. 

Description

GlobalData's clinical trial report, "Glaucoma Global Clinical Trials Review, H2, 2016" provides an overview of Glaucoma clinical trials scenario. This report provides top line data relating to the clinical trials on Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC9405IDBVaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017Jun 2017
Report... 05IB-GMDHC9402IDBMacular Edema - Pipeline Review, H1 2017Jun 2017
Report... 05IB-GMDHC9403IDBRetinal Vein Occlusion - Pipeline Review, H1 2017Jun 2017
Report... 05IB-GMDHC9404IDBRadiodermatitis - Pipeline Review, H1 2017Jun 2017
Report... 01L7-AST5339Electrophoresis Market - Forecast to 2022 Jun 2017
Report... 01L7-HIT2464Healthcare EDI Market - Forecast to 2022 Jun 2017
Report... 05IB-GMDHC9352IDBBenign Prostatic Hyperplasia - Pipeline Review, H1 2017May 2017
Report... 05IB-GMDHC9353IDBSecondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 ...May 2017
Report... 05IB-GMDHC9319IDBNephrotic Syndrome - Pipeline Review, H1 2017May 2017
Report... 05IB-GMDHC9320IDBEnd-Stage Kidney Disease - Pipeline Review, H1 2017May 2017

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-12-21 

Report: Glaucoma Global Clinical Trials Review, H2, 2016

 

Contents

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Glaucoma to Ophthalmology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Glaucoma to Ophthalmology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Glaucoma Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Glaucoma 30
Dec 07, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% 30
Oct 27, 2016: Aerie Pharmaceuticals Reports Positive Topline Efficacy Results of Rocket 4 Phase 3 Trial of Rhopressa (netarsudil ophthalmic solution) 0.02% 30
Oct 17, 2016: Envisia Therapeutics Releases ENV515 (travoprost XR) Phase 2 Data Showing Nine-Month Duration Of Action After A Single Dose In Patients With Glaucoma 31
Oct 10, 2016: Allergan to Showcase Brimonidine Drug Delivery System (Brimonidine DDS) at the 2016 American Academy of Ophthalmology Annual Meeting in Chicago 32
Clinical Trial Profile Snapshots 33
Appendix 560
Abbreviations 560
Definitions 560
Research Methodology 561
Secondary Research 561
About GlobalData 562
Contact Us 562
Disclaimer 562
Source 563
 

List of Tables

List of Tables
Glaucoma Therapeutics, Global, Clinical Trials by Region, 2016* 6
Glaucoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Glaucoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Glaucoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Glaucoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Glaucoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Glaucoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Glaucoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Glaucoma to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 14
Glaucoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Glaucoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Glaucoma to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 17
Glaucoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Glaucoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Glaucoma Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Glaucoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Glaucoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Glaucoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Glaucoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Glaucoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Glaucoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Glaucoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Glaucoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
 

List of Figures

List of Figures
Glaucoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Glaucoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Glaucoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Glaucoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Glaucoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Glaucoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Glaucoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Glaucoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Glaucoma to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 14
Glaucoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Glaucoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Glaucoma to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 17
Glaucoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Glaucoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Glaucoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Glaucoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Glaucoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Glaucoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Glaucoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Glaucoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Glaucoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Glaucoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Glaucoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 561
 

Scope


- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Healthcare 
Pages: 563 

Companies Featured

Novartis AG Allergan Plc Pfizer Inc Santen Pharmaceutical Co Ltd Aerie Pharmaceuticals Inc Merck & Co Inc Valeant Pharmaceuticals International Inc Kowa Company Ltd Sun Pharmaceutical Industries Ltd Mati Therapeutics Inc

 

Reasons to buy this report


- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC9405IDBVaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017Jun 2017
Report... 05IB-GMDHC9402IDBMacular Edema - Pipeline Review, H1 2017Jun 2017
Report... 05IB-GMDHC9403IDBRetinal Vein Occlusion - Pipeline Review, H1 2017Jun 2017
Report... 05IB-GMDHC9404IDBRadiodermatitis - Pipeline Review, H1 2017Jun 2017
Report... 01L7-AST5339Electrophoresis Market - Forecast to 2022 Jun 2017
Report... 01L7-HIT2464Healthcare EDI Market - Forecast to 2022 Jun 2017
Report... 05IB-GMDHC9352IDBBenign Prostatic Hyperplasia - Pipeline Review, H1 2017May 2017
Report... 05IB-GMDHC9353IDBSecondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 ...May 2017
Report... 05IB-GMDHC9319IDBNephrotic Syndrome - Pipeline Review, H1 2017May 2017
Report... 05IB-GMDHC9320IDBEnd-Stage Kidney Disease - Pipeline Review, H1 2017May 2017

Glaucoma Global Clinical Trials Review, H2, 2016

Report 05IC-GDHC4015CTIDB has a rating of 95 percent
Figure of merit assessment for report 05IC-GDHC4015CTIDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 505

Taxonomy Location

The taxonomy on the left shows the ancestors of the Healthcare node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Glaucoma Global Clinical Trials Review, H2, 2016

 

Item Code: 05IC-GDHC4015CTIDB

 
Licence: Single User
Price: $2500.00
 
VAT: 0.0% 
Total: $2500.00 

Feedback

Return to Research and Experts

Cache retrieved and rendered [0.01667s]

--